Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 21 U.S.C. §355 (n)(4)

Pamela Haylock, R.N., M.A.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: **July 24, 2007**

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Application (NDA) 021,801, proposed trade name Orplatna (satraplatin capsules), originally developed by Johnson Matthey Pharmaceuticals, a subsidiary of Johnson Matthey PLC, with licensing rights to Spectrum Pharmaceuticals. Spectrum Pharmaceuticals licensed the global rights to GPC Biotech AG, proposed indication for the treatment of patients with androgen independent (hormone refractory) prostate cancer (HRPC) that has failed prior chemotherapy, I am eligible to receive a waiver under 21 U.S.C. §355(n)(4).

Type of Interest	**Nature**	**Magnitude**
Stock	Competitor	Valued at less than $5,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

/S/
Signature of SGE

June 11, 2007
Date